Back to top
more

National Vision (EYE)

(Delayed Data from NSDQ)

$24.17 USD

24.17
2,576,198

+0.29 (1.21%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $24.23 +0.06 (0.25%) 6:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (183 out of 246)

Industry: Consumer Products - Staples

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

STERIS (STE) Q4 Earnings Fall Shy of Estimates, FY22 View Up

by Zacks Equity Research

STERIS' (STE) fourth-quarter 2021 revenues improved year over year on robust growth across three segments.

Zacks Equity Research

TeleFlex (TFX) Urolift Grows, Organic Sales Hit by Pandemic

by Zacks Equity Research

On the strength of a successful 2020 campaign, Teleflex (TFX) doubles the awareness for UroLift in the targeted population of men with BPH.

Zacks Equity Research

LabCorp's (LH) Pixel Kit Gets EUA for Younger Population

by Zacks Equity Research

LabCorp (LH) becomes the first major commercial laboratory to offer a COVID-19 PCR Test Home Collection Kit for children and adolescents.

Zacks Equity Research

Abbott (ABT) Receives CE Mark for Latest Navitor TAVI System

by Zacks Equity Research

Abbott's (ABT) latest-generation Navitor TAVI system features improvements to reduce or eliminate a backflow of blood around valve implants.

Zacks Equity Research

Here's Why You Should Buy Henry Schein (HSIC) Stock Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) on solid first-quarter performance and strategic deals.

Zacks Equity Research

Medtronic's (MDT) Coronary Market Share Grows Amid Pandemic

by Zacks Equity Research

In Gastrointestinal, Medtronic (MDT) is witnessing some modest share gains, driven in part by its partnership with the NHS in England.

Zacks Equity Research

National Vision (EYE) Q1 Earnings Top Estimates, View Up

by Zacks Equity Research

According to National Vision (EYE), increased demand for low-cost eye exams, glasses and contact lenses boosts first-quarter performance.

Zacks Equity Research

Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) on strong quarterly results and robust pump sales.

Zacks Equity Research

National Vision (EYE) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of 45.45% and 3.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tandem (TNDM) Global Growth Strong, Costs Continue to Rise

by Zacks Equity Research

Tandem Diabetes (TNDM) is witnessing high international demand for the t:slim X2 pump.

Zacks Equity Research

Here's Why You Should Add Bruker (BRKR) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.

Zacks Equity Research

Here's Why You Should Buy Amedisys (AMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Amedisys (AMED) on bright Personal Care prospects, and strategic acquisitions and partnerships.

Kevin Cook headshot

Bull of the Day: National Vision (EYE)

by Kevin Cook

As a nation, optical care needs are rising and re-opening trends are spurring a big catch-up on exams

Zacks Equity Research

Aurora Cannabis (ACB) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Aurora Cannabis' (ACB) sturdy consumer cannabis sales are likely to have benefited its performance in the fiscal third quarter.

Zacks Equity Research

Here's Why You Should Hold on to Illumina (ILMN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of its products.

Zacks Equity Research

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its masks.

Aditi Saraogi headshot

Is a Surprise Coming for National Vision (EYE) This Earnings Season?

by Aditi Saraogi

National Vision (EYE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Here's Why You Should Buy Boston Scientific (BSX) Stock Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) owing to its solid first-quarter performance and impressive value-added acquisitions.

Zacks Equity Research

Here's Why You Should Buy National Vision (EYE) Stock Now

by Zacks Equity Research

Investors are optimistic about National Vision (EYE) backed by its improvement in comparable store sales (comps) in eyeglasses and contact lens.

Zacks Equity Research

Medtronic (MDT) to Enhance Patient Care via Digital Portal

by Zacks Equity Research

Medtronic's (MDT) first patient-centric digital health platform is expected to provide better outcome for patients undergoing the company's SCS therapy.

Zacks Equity Research

Schrodinger (SDGR) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Schrodinger's (SDGR) first-quarter results are likely to reflect benefits from collaborations.

Zacks Equity Research

What's in Store for Asensus Surgical's (ASXC) Q1 Earnings?

by Zacks Equity Research

Asensus Surgical's (ASXC) first-quarter results are likely to reflect benefits from regulatory approvals and collaboration.

Zacks Equity Research

National Vision (EYE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

National Vision (EYE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

National Vision (EYE) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

National Vision's (EYE) transitions of five additional Walmart Vision Centers in 2020, which have become operative of late, are expected to post positive Q1 results.

Zacks Equity Research

Why Is National Vision (EYE) Up 2.2% Since Last Earnings Report?

by Zacks Equity Research

National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.